The FDA has approved Medtronic Amplia MRI Quad CRT-D SureScan and Compia MRI Quad CRT-D SureScan systems for the treatment...
Objective: There is an association between latitude, relative vitamin D deficiency and risk of multiple sclerosis (MS), and an association between vitamin D and disease progression.
The FDA has requested data from AstraZeneca as part of its investigation a possible association between use of Onglyza for...
Background: Vitamin D has been reported to be associated with many allergic diseases. There are a limited number of the studies of vitamin D supplementation in patients with chronic spontaneous urticaria (CSU). U).
This literature review and meta-analysis aimed to determine the association between deficiency of vitamin D, or 25-hydroxyvitamin D, and Parkinson's disease, and whether vitamin D from supplements and sunlight...
Lumicell, Inc., announced the FDA approved the company’s New Drug Application (NDA) for its Lumisight (pegulicianine) optical imaging agent and its Premarket Approval (PMA) application for Lumicell Direct Visualization System (DVS), together referred to as LumiSystem
Merck Inc. known as MSD outside of the United States and Canada, announced that Health Canada has approved a new indication for Prevymis (letermovir) for the prophylaxis of cytomegalovirus (CMV) disease in adult kidney transplant recipients at high risk (Donor CMV-seropositive/Recipient CMV-seronegative [D+/R-]).
Zydus Cadila announced that the company has received the Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D the world's first Plasmid DNA Vaccine for COVID-19.
Background: There is growing literature suggesting a link between vitamin D and asthma lung function, but the results from systematic reviews are conflicting.
Our current knowledge of the benefits and drawbacks of vitamin D supplements in pregnancy is insufficient to recommend their use, leading a team of researchers to analyse the current evidence with the aim of clarifying this contentious issue.